cyproterone acetate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiandrogens 766 427-51-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cyproterone acetate
  • cyproviron
An agent with anti-androgen and progestational properties. It shows competitive binding with dihydrotestosterone at androgen receptor sites.
  • Molecular weight: 416.94
  • Formula: C24H29ClO4
  • CLOGP: 3.96
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 60.44
  • ALOGS: -5.44
  • ROTB: 3

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 10.28 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1974 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Meningioma 741.92 34.34 115 895 3629 53344427
Congenital cyst 118.94 34.34 14 996 42 53348014
Small for dates baby 65.47 34.34 15 995 3737 53344319
Epilepsy 51.24 34.34 19 991 25748 53322308
Prosopagnosia 39.25 34.34 5 1005 33 53348023
Frontotemporal dementia 36.34 34.34 6 1004 268 53347788
Low birth weight baby 34.40 34.34 10 1000 6327 53341729

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Meningioma 334.70 44.02 52 650 1423 32511401
Rhabdomyolysis 62.88 44.02 30 672 67235 32445589

Pharmacologic Action:

SourceCodeDescription
MeSH PA D000726 Androgen Antagonists
MeSH PA D006727 Hormone Antagonists
CHEBI has role CHEBI:35497 antiandrogen
CHEBI has role CHEBI:59826 progestins
CHEBI has role CHEBI:176497 anti-aging drugs
MeSH PA D000970 Antineoplastic Agents
MeSH PA D003270 Contraceptive Agents
MeSH PA D003272 Contraceptive Agents, Male
MeSH PA D012102 Reproductive Control Agents

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Androgen receptor Nuclear hormone receptor ANTAGONIST IC50 7.43 WOMBAT-PK IUPHAR
Glucocorticoid receptor Nuclear hormone receptor IC50 7.80 WOMBAT-PK
Mu-type opioid receptor GPCR Ki 6.05 DRUG MATRIX
Progesterone receptor Nuclear hormone receptor IC50 9.68 WOMBAT-PK
Androgen receptor Transcription factor IC50 4.74 CHEMBL
Progesterone receptor Transcription factor Ki 8.32 DRUG MATRIX
Adenosine receptor A1 GPCR IC50 8.30 CHEMBL

External reference:

IDSource
N0000167457 NUI
D01368 KEGG_DRUG
2098-66-0 SECONDARY_CAS_RN
C0056855 UMLSCUI
CHEBI:50743 CHEBI
CHEBI:50742 CHEBI
CA4 PDB_CHEM_ID
CHEMBL139835 ChEMBL_ID
D017373 MESH_DESCRIPTOR_UI
DB04839 DRUGBANK_ID
9880 PUBCHEM_CID
2865 IUPHAR_LIGAND_ID
2050 INN_ID
4KM2BN5JHF UNII
5284537 PUBCHEM_CID
E61Q31EK2F UNII
22054 RXNORM
003475 NDDF
004825 NDDF
126119006 SNOMEDCT_US
126120000 SNOMEDCT_US
96370002 SNOMEDCT_US
D003534 MESH_DESCRIPTOR_UI
C0010621 UMLSCUI

Pharmaceutical products:

None